Literature DB >> 10952783

Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas.

H Mineta1, K Miura, T Ogino, S Takebayashi, K Misawa, Y Ueda, I Suzuki, M Dictor, A Borg, J Wennerberg.   

Abstract

Vascular endothelial growth factor (VEGF) has been identified as the substance that increases the permeability and proliferation of vascular endothelial cells. We examined the clinical significance of VEGF expression in 60 head and neck squamous cell carcinomas using the methods of Western blot, immunohistochemistry, and reverse transcriptase-polymerase chain reaction (RT-PCR), comparatively, and analysed the relationship between VEGF status in Western blot and tumour size, lymph-node status, histologic grade and disease-free survival (DFS) rate. Western blot analysis revealed high VEGF expressors (tumour/normal tissue density >/= 3-fold) in 26 patients (43%) and low VEGF expressors (< 3-fold) in 34 patients (57%). The results of the Western blot analysis correlated significantly with those of the RT-PCR (P = 0.00007) or immunohistochemistry (P = 0. 00006). High VEGF expressors are associated with the progression of lymph-node spread (P = 0.0009), which are correlated with poor DFS. The 2-year DFS rate of high VEGF expressors (30%) was significantly lower than that of low VEGF expressors (78%) (P = 0.0008). Multivariate analysis showed VEGF expression and stage were independent predictors for the DFS (P = 0.045 and 0.041, respectively). VEGF expression may play an important role in progression of HNSCC. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952783      PMCID: PMC2363534          DOI: 10.1054/bjoc.2000.1357

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  55 in total

1.  Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer.

Authors:  H Kumar; K Heer; P W Lee; G S Duthie; A W MacDonald; J Greenman; M J Kerin; J R Monson
Journal:  Clin Cancer Res       Date:  1998-05       Impact factor: 12.531

2.  Tumor angiogenesis as a prognostic factor in laryngeal cancer.

Authors:  J D Murray; G W Carlson; K McLaughlin; M Pennington; M Lynn; P B DeRose; J K Williams; C Cohen
Journal:  Am J Surg       Date:  1997-11       Impact factor: 2.565

3.  Vascular endothelial growth factor expression in early stage ovarian carcinoma.

Authors:  P J Paley; K A Staskus; K Gebhard; D Mohanraj; L B Twiggs; L F Carson; S Ramakrishnan
Journal:  Cancer       Date:  1997-07-01       Impact factor: 6.860

4.  Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance.

Authors:  P Salven; P Heikkilä; A Anttonen; M Kajanti; H Joensuu
Journal:  Mod Pathol       Date:  1997-11       Impact factor: 7.842

5.  AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor.

Authors:  K Weindel; D Marmé; H A Weich
Journal:  Biochem Biophys Res Commun       Date:  1992-03-31       Impact factor: 3.575

6.  Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma.

Authors:  M Moriyama; S Kumagai; S Kawashiri; K Kojima; K Kakihara; E Yamamoto
Journal:  Oral Oncol       Date:  1997-09       Impact factor: 5.337

7.  Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma.

Authors:  T Shibusa; N Shijubo; S Abe
Journal:  Clin Cancer Res       Date:  1998-06       Impact factor: 12.531

8.  Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E.

Authors:  P A Scott; K Smith; R Poulsom; A De Benedetti; R Bicknell; A L Harris
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

9.  Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer.

Authors:  S I Ishigami; S Arii; M Furutani; M Niwano; T Harada; M Mizumoto; A Mori; H Onodera; M Imamura
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

10.  Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas.

Authors:  G Fontanini; L Boldrini; S Chinè; F Pisaturo; F Basolo; A Calcinai; M Lucchi; A Mussi; C A Angeletti; G Bevilacqua
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

View more
  26 in total

1.  Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.

Authors:  O Straume; L A Akslen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.

Authors:  Athanassios Argiris; Shuli Li; Panayiotis Savvides; James P Ohr; Jill Gilbert; Marshall A Levine; Arnab Chakravarti; Missak Haigentz; Nabil F Saba; Chukwuemeka V Ikpeazu; Charles J Schneider; Harlan A Pinto; Arlene A Forastiere; Barbara Burtness
Journal:  J Clin Oncol       Date:  2019-10-16       Impact factor: 44.544

Review 3.  Molecular mechanisms of head and neck cancer.

Authors:  Amit M Deshpande; David T Wong
Journal:  Expert Rev Anticancer Ther       Date:  2008-05       Impact factor: 4.512

Review 4.  Therapeutics role of olive fruits/oil in the prevention of diseases via modulation of anti-oxidant, anti-tumour and genetic activity.

Authors:  Arshad H Rahmani; Aqel S Albutti; Salah M Aly
Journal:  Int J Clin Exp Med       Date:  2014-04-15

Review 5.  Targeted therapy in head and neck cancer.

Authors:  S K Kundu; M Nestor
Journal:  Tumour Biol       Date:  2012-02-29

6.  VEGF expression and angiogenesis in oral squamous cell carcinoma: an immunohistochemical and morphometric study.

Authors:  Claudiu Mărgăritescu; Daniel Pirici; Alin Stîngă; Cristiana Simionescu; Marius Raica; Laurentiu Mogoantă; Alex Stepan; Domenico Ribatti
Journal:  Clin Exp Med       Date:  2010-04-08       Impact factor: 3.984

7.  Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.

Authors:  Benedikt Kramer; Johannes David Schultz; Clemens Hock; Alexander Sauter; Boris A Stuck; Karl Hörmann; Richard Birk; Christoph Aderhold
Journal:  Oncol Lett       Date:  2017-03-13       Impact factor: 2.967

8.  Clinical and molecular prognostic factors in operable laryngeal cancer.

Authors:  Konstantinos Vlachtsis; Angelos Nikolaou; Konstantinos Markou; George Fountzilas; Ioannis Daniilidis
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-01       Impact factor: 2.503

9.  Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.

Authors:  A M Jubb; T Q Pham; A M Hanby; G D Frantz; F V Peale; T D Wu; H W Koeppen; K J Hillan
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

10.  UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.

Authors:  Nobutaka Nagai; Keiji Mukai; Eiji Hirata; Hong Hua Jin; Masaaki Komatsu; Mayu Yunokawa
Journal:  Med Oncol       Date:  2007-10-30       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.